Observational Study Evaluating the Accuracy of a Blood Test for Diagnosing Colorectal Cancer Using Molecular Markers and AI-Identified Risk Factors

What this Trial Is About

This research aims to evaluate the false positive rate of a blood test that uses molecular biomarkers and risk factors identified by artificial intelligence tools. The study includes 250 patients diagnosed with various cancers and gastrointestinal diseases, excluding colorectal cancer. The main goal is to determine if the blood test has a low false positive rate in this group. Participants will provide a blood sample for molecular analysis as part of their regular medical care. The study includes patients with different cancer types such as breast cancer, bladder cancer, leukemia, lung cancer, and inflammatory bowel diseases. This is an observational study without treatment interventions. During the study, participants will donate a blood sample and provide consent to access their clinical risk factors. Researchers will monitor the accuracy of the blood test over 36 months by measuring the rate of false positives. The total participation involves routine care procedures and sample collection for molecular testing, with no additional invasive procedures.

Observational Cross-reactivity Study for Colorectal Cancer Diagnosis